Kornimate/medical-research-clean huggingface dataset:
effectiveness of sealants on molars

Conditions: Tooth Decay

Summary: currently, the real scope of sealants (as) is poorly documented in temporary dentition and its effectiveness has not been demonstrated. yet it seems reasonable that the as in temporary dentition could slow the specific development of carious lesions in early childhood. in addition, this non-invasive approach could delay the conventional food and thus save financial costs for more complex treatments. finally, the installation of as could afford, as demonstrated in adult teeth, lowering the cariogenic bacteria prevalence engaged in the caries process.

currently, the real scope of sealants (as) is poorly documented in temporary dentition and its effectiveness has not been demonstrated. yet it seems reasonable that the as in temporary dentition could slow the specific development of carious lesions in early childhood. in addition, this non-invasive approach could delay the conventional food and thus save financial costs for more complex treatments. finally, the installation of as could afford, as demonstrated in adult teeth, lowering the cariogenic bacteria prevalence engaged in the caries process. main objective: to evaluate the effect of as on caries incidence in the deciduous dentition obtained over a period of three years, taking into account the risk of caries established initially. secondary objectives: 1. to assess the prevalence and caries attack sites at the end of each year 2. estimate the retention rate (partial or complete) of the as during the study 3. determine the cost savings of treatment during the trial period

Eligibility criteria:
inclusion criteria: * children who have at least two pairs (test / control) of healthy molars with occlusal surface or non cavitary initial injury. * children available for a follow-up 3 years * children being affiliated or beneficiary in a health insurance plan exclusion criteria: * children involved in other research in the same field * child is exclusion period determined by previous research * children participating in research in the last three months its inclusion * parents do not understand french. * children deprived of liberty. * child participation refusal * refusal to participate in either of the parents or legal representative
the effect of hypnotherapeutic sound-files on the sleep of parents in the neonatal unit.

Conditions: Parents; Sleep; Infant, Premature; Hypnosis

Summary: the goal of this randomised study is to learn about, the effect of hypnotherapeutic sound-files on the sleep of parents of infants in the neonatal unit. the main questions it aims to answer are: * can hypnotherapeutic sound-files make parents of infants in the neonatal unit sleep longer and better? * does hypnotherapeutic sound-files effect the state anxiety score of parents of infants in the neonatal unit? participants will have access to sound-files and: * wear actigraphy sleep registration * complete state-trait anxiety score


Eligibility criteria:
inclusion criteria: * parents of a newborn in the neonatal unit at randers regional hospital exclusion criteria: * age under 18 * hearing disability to an extend where sound-files cannot be used * psychotic diagnosis, including schizophrenia and personality disorder * already using hypnotherapeutic sound-files * the use of sleep medication.
cytoxan, epirubicin and capecitabine in women with breast cancer

Conditions: Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer

Summary: the purpose of this study is to find out what effects (good and bad) a combination of cytoxan, epirubicin, and capecitabine have on women with stage ii/ii/iiia breast cancer.

* each treatment cycle lasts 21 days and patients will participate in a least 4 cycles, but no more than 6 cycles of treatment. * patients will receive cytoxan (cyclophosphamide) and epirubicin intravenously on day 1 of each treatment cycle. on days 4-17 of each cycle, patients will take capecitabine orally twice a day. * while on the study patients will be required to complete a diary of they capecitabine treatment. * blood tests will be performed each week along with surveys at the beginning of the trial and certain follow-up visits to evaluate the patient's experience with the oral chemotherapy. * patients will be on the treatment for 12-18 weeks depending upon whether or not the disease progresses or the patient develops inacceptable side effects.

Eligibility criteria:
inclusion criteria: * histologically confirmed stage i-iii breast cancer. if stage i, should be deemed of sufficiently high risk of developing recurrent disease to warrant participation. * 18 years of age or older * anc \> 1,000/mm3 * platelet count \> 100,000/mm3 * hemoglobin \> 10 * creatinine \< 2.0 * sgot \< 2 x uln * bilirubin \< 1.5mg/dl * able to swallow and retain oral medication * lvef greater than or equal to 50% * ecog performance status of 0 or 1 exclusion criteria: * pregnant or lactating * prior malignancy within 5 years (excluding squamous or basal cell skin cancers) * prior chemotherapy within 5 years * prior anthracycline therapy * serious comorbid physical or psychological condition

Keywords: breast cancer cytoxan epirubicin capecitabine
a dose-finding study of a combination of imatinib and bkm120 in the treatment of 3rd line gist patients

Conditions: 3rd Line GIST

Summary: the purpose of this study is to determine a maximum tolerated dose and/or recommended phase 2 dose of a combination of imatinib and bkm120 in the treatment of 3rd line gist patients.


Eligibility criteria:
inclusion criteria: 1. male or female patients ≥ 18 years of age 2. who performance status (ps) of 0-2 3. histologically confirmed diagnosis of gist that is unresectable or metastatic 4. available tissue specimen: * dose-escalation cohorts: patients must have available archival tumor tissue which can be shipped during the course of the study * dose-expansion cohort: patients must have available archival tumor tissue which can be shipped during the course of the study and must agree to a fresh pre-treatment biopsy. 5. failed prior therapy with imatinib followed by sunitinib for the treatment of unresectable or metastatic gist. note the following specific criteria for the two phases of the trial: * dose-escalation cohorts: patients who failed prior therapy with imatinib and then have failed therapy with sunitinib. treatment failure may be due to either disease progression on therapy (both imatinib and sunitinib) or intolerance to therapy (sunitinib). dose-escalation cohort patients may have had additional lines of therapy not limited to imatinib and sunitinib. * dose-expansion cohort: patients must have documented disease progression on both imatinib and sunitinib. in addition, patients may have had no more than two lines of prior therapy (i.e. treatment with imatinib followed by treatment with sunitinib). * adjuvant imatinib will not count as a prior course of imatinib for the purposes of this criterion exclusion criteria: 1. previous treatment with pi3-k inhibitors 2. a medical history of any of the following mood disorders as judged by the investigator or a psychiatrist: * medically documented history of or active major depressive episode, bipolar disorder (i or ii), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or thoughts, or homicidal thoughts (immediate risk of doing harm to others) * ≥ ctcae grade 3 anxiety 3. when completing the patient questionnaires at screening: * meets the cut-off score of ≥ 10 in the nine item depression scale of the patient health questionnaire (phq-9) or a cut-off of ≥ 15 in the generalized anxiety disorder assessment (gad 7) mood scale respectively, or * selects positive response of 1, 2, 3 to question number 9 regarding potential for suicidal thoughts or ideation in the phq-9 (independent of the total score of the phq-9) 4. severe and/or uncontrolled concurrent medical condition that, in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. acute or chronic liver, pancreatic, severe renal disease considered unrelated to study disease, chronic pulmonary disease including dyspnea at rest from any cause). 5. poorly controlled diabetes mellitus (defined as hba1c \> 8%) other protocol-defined inclusion/exclusion criteria may apply.

Keywords: imatinib mesylate bkm120 gist
comparative analysis of two animal-derived adms in irradiated implant-based reconstruction

Conditions: Breast Implant; Complications; Breast Implant Infection; Implant Capsular Contracture; Breast Seroma; Breast Implant Protrusion; Breast Cancer

Summary: the goal of this retrospective observational trial is to compare two different devices, used in implant-based breast reconstruction, called acellular dermal matrices, which are a sort of collagen patch that integrates with the tissues of the patient and helps in contrasting the collateral effects of radiotherapy (capsular contracture, implant loss) the main questions the study aims to answer are: * is one of the two matrices better than the other? (better results with fewer complications) * is there a group of patients who benefit more than another from the use of this type of devices? * is there an adm which works better in one specific subgroup of patients? participants have undergone mastectomy, radiotherapy and implant reconstruction with the aid of two different kinds of acellular dermal matrices. researchers will compare patients who receive the porcine-derived adm and the patients who receive bovine-derived adm to see if there is a difference in terms of capsular contracture reduction, aestethic result and complications.

radiotherapy is highly effective in breast cancer treatment, yet it impairs satisfactory implant-based reconstruction, due to high rates of capsular contracture and implant loss. this said, a fervent investigtion exists upon solutions that can make implant-based reconstruction safer and aesthetically satisfying, including the use of acellular dermal matrices. we retrospectively want to analyze our adm-assisted post-rt implant-based breast reconstructions comparing two different matrices (porcine and bovine), when autologous reconstruction was contraindicated, to assess eventual differences in efficacy and risk profile of the devices. we want to further stratify the population in 4 groups based on clinical presentation to assess if there was a group where adms proves to perform better (group a - previous quadrantectomy, group b - previous mastectomy and expander reconstruction, group c - previous mastectomy and implant reconstruction, group d - prior quadrantectomy followed by mastectomy and implant reconstruction).

Eligibility criteria:
inclusion criteria: * at least 6 months follow up * breast reconstruction with implant + acellular dermal matrix after mastectomy and radiotherapy exclusion criteria: * mastectomy flap \<1 cm * autoimmune disease * prolonged use of corticosteroids

Keywords: implant-based breast reconstruction adm radiation therapy irradiated breast
assessment of risk factors for childhood obesity and nutrition education intervention on infant growth and development

Conditions: Childhood Obesity

Summary: the period from conception to 2 years of age ('first 1000 days') has been recognized as a critical period for long-lasting programming effects on later obesity and associated ncd and a window of opportunity to implement intervention for reducing and treating childhood obesity. however, there is a dearth of prospective intervention studies that address this nutritional problem in jamaica and there are no reports of sustainable intervention. jamaica is a middle income country in which overweight and obesity in children are also increasing at an alarming rate. the investigators in jamaica are seeking to provide a more comprehensive knowledge on the link between early life nutrition and later childhood health and to assess the impact of an intervention of infant feeding counselling/education in mothers on growth and body composition in their offspring.

at least 41 million children younger than 5 years are overweight or obese most of whom reside in low-income and middle-income countries (lmic). obese children tend to remain obese in adulthood predisposing to the huge personal health and economic burden of the non-communicable diseases (ncd). several early life factors identified to contribute to development of obesity and adverse metabolic profile; pre-pregnancy underweight and overweight, high weight gain in early pregnancy in addition to inappropriate infant feeding pattern and rapid weight gain in early life have major role. the aims of the study are:1) to assess intrauterine and postnatal risk factors for childhood obesity in children followed from the second trimester in mother's pregnancy to age 1 year and 2) to assess the impact of a nutrition-based educational intervention on infant feeding, growth and body composition in the first year of life. this study design is a cluster randomized clinical trial with key outputs being : 1) the use of deuterium dilution method to provide new data on body composition of mothers from during pregnancy and during infancy in addition to obtain accurate measurement of breastmilk intake 2) new data on the relationship between maternal body composition and/or infant body composition and non-communicable disease risk factors; 3) new data on the impact of a nutrition-based educational on infant's growth and body composition.

Eligibility criteria:
inclusion criteria: * women (18-40 years) * women 30 -32 weeks gestation * first or second pregnancy * healthy term infants ( \> 37 completed weeks) * infants with birthweight \>2.5kg) exclusion criteria: * pre-gestational diabetes * pre-gestational hypertension * sickle cell disease * hiv infection, * psychiatric disorder * gestational diabetes * infants with congenital abnormalities * infants with chromosomal disorders * infants admitted in neonatal period \> 48 hours
comparative evaluation of ctg with and without rhpdgf- bb using modified coronally advanced tunnel for root coverage

Conditions: Gingival Recession

Summary: the present study is a human, prospective, single centre, single blind, comparative controlled randomized clinical trial for the treatment of miller's class i, ii or combination of class i and ii mandibular recession and comparing the clinical outcomes prior to and 6 months after treatment. the trial is in accordance to the consolidated standards of reporting trials (consort) criteria, 2010.

24 recession defects were selected in patients who were systemically and periodontally healthy, satisfying the determined inclusion criteria. patients with at least two or more teeth having miller's class i , ii or combination of class i and ii mandibular recession defects were included in the study. a detailed, thorough medical and dental history was obtained and each patient was subjected to comprehensive clinical and radiological examination. all patients were informed about the nature of the study, surgical procedure involved, potential benefits and risks associated with the surgical procedure and a written informed consent was obtained from all patients. the patients were assigned into two treatment groups (test and control). the test group was treated with recombinant human platelet derived growth factor-bb and modified coronally advanced tunnel +connective tissue graft whereas the control group was treated by modified coronally advanced tunnel +connective tissue graft alone.

Eligibility criteria:
inclusion criteria: * patients fulfilling the following criteria were included in the study:- * two or more teeth with miller's class i and ii or combined class i and ii recession defects in mandibular anteriors. * age group 21-58 years. * patients with healthy or treated periodontal conditions. * patients willing to participate in the study. * absence of uncontrolled medical conditions. * patients with full mouth plaque score \</= 10%(o'leary 1972) * patients with esthetic concerns. * patients with thick gingival biotype \>0.8mm exclusion criteria: * pregnant or lactating females. * tobacco smoking. * uncontrolled medical conditions. * untreated periodontal conditions. * use of systemic antibiotics in the past 3 months. * patients treated with any medication known to cause gingival hyperplasia. * drug and alcohol abuse * no occlusal interferences. * patient with a known hypersensitivity to rhpdgf-bb.
pioglitazone and losartan provides additional renoprotection

Conditions: Type 2 Diabetes; Diabetic Nephropathy

Summary: peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin ii receptor antagonist losartan reduced the levels of proteinuria.whether combination therapy with pioglitazone and losartan provides additional renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.


Eligibility criteria:
inclusion criteria: * fasting plasma glucose (fpg) level of 3.3-9.0mmol/l * 2h plasma glucose level of 7.5-13 mmol/l * serum creatinine values between 190 and 660umol/l * two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is \>150mg * informed consent exclusion criteria: * type1 diabetes or nondiabetic renal disease * abnormal liver function * heart dysfunction

Keywords: pioglitazone losartan proteinuria end stage renal disease (esrd)
fingolimod in covid-19

Conditions: Coronavirus Disease (COVID-19)

Summary: although immune-inflammatory treatment is not routinely recommended to be used for sars-cov-2 pneumonia, according to the pathological findings of pulmonary oedema and hyaline membrane formation, timely and appropriate use of immune modulator together with ventilator support should be considered for the severe patients to prevent ards development. the sphingosine-1-phosphate receptor regulators fingolimod (fty720) is an effective immunology modulator which has been widely used in multiple sclerosis.the aim of this study was to determine whether the efficacy of fingolimod for a novel coronavirus disease (covid-19).


Eligibility criteria:
inclusion criteria: * the patients who were diagnosed with the common type of ncp (including severe risk factors) and severe cases of new coronavirus pneumonia; * aged 18 to 85 years; * patients or authorized family members volunteered to participate in this study and signed informed consent. exclusion criteria: * patients with any history of bradyarrhythmia or atrioventricular blocks * patients who are participating in other drug clinical trials; * pregnant or lactating women; * alt / ast\> 5 uln, neutrophils \<0.5, platelets less than 50; * definite diagnosis of rheumatic immune-related diseases; * long-term oral anti-rejection or immunomodulatory drugs; * patients with active pulmonary tuberculosis, with definite bacterial and fungal infections.
impact of aerobic training and combined in inflammatory markers in patients with adolescent idiopathic scoliosis

Conditions: Scoliosis; Adolescent Scoliosis

Summary: inflammatory markers have been analyzed in several diseases of unknown etiology, in the expectation of increasing therapeutic perspectives. this possibility arises from the different levels of tissue injury with low-grade chronic inflammation that have been observed in studies in which the markers were not evaluated traditionally, and today have influenced clinical management. the investigators aimed, therefore, to evaluate the inflammatory markers in patients with ais before and after aerobic and combined exercise training.

inflammatory markers have not been evaluated in adolescent idiopathic scoliosis (ais), but this deformity potentially involves various musculoskeletal structures permanently, which justifies the analysis. a low-grade chronic inflammation may be related to the lower capacity in exercise performance observed in this population, which must be stimulated to perform standardized physical activity.

Eligibility criteria:
inclusion criteria: * thoracic curvature ≥ 45 degrees * indication for surgical treatment of spinal deformity * absence of pulmonary, cardiac, articular or neurological disorder, atopic dermatitis and previous or current allergy * agree part in the research with a assent statement and the person responsible with the consent form and informed exclusion criteria: * acknowledged chronic liver or kidney inflammatory disease * use of corticosteroids, acetylsalicylic acid or other nonhormonal anti-inflammatory clinical or laboratorial evidence of infection * severe obesity

Keywords: adolescent idiopathic scoliosis inflammatory markers exercise
nonspecific neck pain

Conditions: Non Specific Neck Pain

Summary: the goal of this a randomized control trial is to carried out to examine graston technique (gt) and muscle energy method (met) impact on nonspecific neck pain compared to traditional physiotherapy treatment (tpt), this study aims to contrast between the outcomes of gt and met on both pain intensity and functional disability in patients. each participant was assigned a unique number, and then those numbers were randomly divided into three groups. three groups were formed from a random selection of participants: gt group (a): received 12 sessions of gt and (tpt) over the course of four weeks (three sessions per week). met group (b): received 12 sessions of met treatment and (tpt) over a period of four weeks (three sessions per week). control group (c): received 12 sessions of traditional physiotherapy (tpt) over a period of four weeks (three sessions per week).

pain intensity (vas) it was utilized to evaluate the degree of pain both before and after treatment. subjects were asked to rate their pain on a scale from 0 (no pain) to 10 (extreme pain). specifically, a line representing 10 centimeters was used as the scale's visual representation. distance from zero to the respondent's mark was then used to approximate the sufferer's level of discomfort. functional disability (ndi) the neck disability index (ndi) is a 10-item questionnaire used to assess the functional impairment caused by neck pain. the questionnaire covers a wide range of topics related to one's everyday life, including but not limited to: personal care, heavy lifting, work, driving, sleeping, playing, recreational, pain level, concentration, and headache. scores range from 0 (no disability) to 5 (severe disability) for each question, with the total score out of 100 determined by adding and doubling the scores for each question. if a patient has a high ndi score, they report being more disabled as a result of their neck pain. patients have identified a 5-10% improvement as the "minimally clinically meaningful change." this study excluded any patient with: symptoms or signs of upper motor neuron disease, vestibulobasilar insufficiency, and amyotrophic lateral sclerosis. cervical spine fracture, cases of disc prolapse that have been diagnosed (27), prior cervical or thoracic spine surgery.

Eligibility criteria:
inclusion criteria: * non specific neck pain exclusion criteria: * symptoms or signs of upper motor neuron disease, vestibulobasilar insufficiency, and amyotrophic lateral sclerosis. cervical spine fracture. cases of disc prolapse that have been diagnosed. prior cervical or thoracic spine surgery, (28).

Keywords: graston technique